Staphylococcal enterotoxin C (SEC), a bacterial superantigenic exotoxin, is commonly produced by invasiveStaphylococcus aureus isolates, especially methicillin-resistant strains and isolates from animal diseases. We constructed and expressed a nontoxic mutant SEC (mSEC) and investigated whether immunization with mSEC, which is devoid of superantigenic activity, can protect against S. aureus infection. Mice were immunized with mSEC and challenged with viable S. aureus. The bacterial counts in the organs of mSEC-immunized mice were significantly lower and the survival rate was higher than the corresponding values for the control group. Immunization with mSEC strongly induced the production of T-helper 2 type antibodies, immunoglobulin G1, and immunoglobulin G2b. The production of interleukin-10 (IL-10) and IL-4 was significantly greater in immunized mice challenged with S. aureus than in the control mice, whereas the production of gamma interferon (IFN-␥) was significantly decreased in the immunized mice. The cytokine response in a spleen cell culture that was stimulated with heat-killed S. aureus or SEC showed that immunization with mSEC inhibited IFN-␥ production and up-regulated IL-10 production in vitro. Furthermore, IFN-␥ and tumor necrosis factor alpha production in vitro was significantly inhibited by sera from mSEC-immunized mice but not by sera from control mice. These results suggest that immunization with mSEC devoid of superantigenic properties provides protection against S. aureus infection and that the protection might be mediated by SEC-specific neutralizing antibodies.Staphylococcus aureus is an important bacterial pathogen in human infections and animal diseases (5, 28, 39). The emergence of antibiotic resistance among clinical isolates has made treatment of staphylococcal infections difficult. To prevent S. aureus infection, a variety of whole staphylococcal preparations, including live, heat-killed, and formalin-fixed preparations of S. aureus cells, have been investigated as vaccines in clinical and veterinary trials. None of these has shown a convincing benefit in patients or farm animals (15,23,28). The mechanism for protecting hosts against staphylococcal infections is still not fully understood.Staphylococcal enterotoxins (SEs), which are bacterial superantigenic proteins produced by S. aureus, play important roles in establishing and maintaining infections (7). Staphylococcal enterotoxin C (SEC) is commonly produced by invasive S. aureus isolates, especially methicillin-resistant S. aureus (MRSA) strains, and can cause severe pathologies. Previous studies have shown that the majority of MRSA in the United States produce SEC or SEB at very high concentrations (37). The majority of S. aureus isolates from bovine mastitis also produce large amounts of SEC (8,9,11). These toxins have a significant economic impact on health care and the dairy industry. There is a considerable need for development of vaccines and therapeutic approaches capable of eliminating the toxicity of these compounds (37)....